Cerus Past Earnings Performance

Past criteria checks 0/6

Cerus has been growing earnings at an average annual rate of 17.6%, while the Medical Equipment industry saw earnings declining at 2.5% annually. Revenues have been growing at an average rate of 17.9% per year.

Key information

17.6%

Earnings growth rate

22.9%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate17.9%
Return on equity-36.5%
Net Margin-11.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Cerus makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:CU2 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24176-207458
30 Jun 24170-247261
31 Mar 24164-327465
31 Dec 23156-377668
30 Sep 23154-508172
30 Jun 23153-518571
31 Mar 23156-468467
31 Dec 22162-438364
30 Sep 22158-388261
30 Jun 22154-428360
31 Mar 22145-498362
31 Dec 21131-548163
30 Sep 21119-607865
30 Jun 21107-617466
31 Mar 2197-617064
31 Dec 2092-606764
30 Sep 2085-626564
30 Jun 2079-666564
31 Mar 2076-696663
31 Dec 1975-716660
30 Sep 1970-716456
30 Jun 1968-676251
31 Mar 1965-625947
31 Dec 1861-585743
30 Sep 1861-535538
30 Jun 1856-525335
31 Mar 1850-565334
31 Dec 1744-615334
30 Sep 1737-635235
30 Jun 1737-645234
31 Mar 1737-655134
31 Dec 1637-634931
30 Sep 1637-644830
30 Jun 1635-654630
31 Mar 1634-634627
31 Dec 1534-564626
30 Sep 1534-614524
30 Jun 1536-564323
31 Mar 1536-484123
31 Dec 1436-393822
30 Sep 1436-243421
30 Jun 1436-343318
31 Mar 1438-333117

Quality Earnings: CU2 is currently unprofitable.

Growing Profit Margin: CU2 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CU2 is unprofitable, but has reduced losses over the past 5 years at a rate of 17.6% per year.

Accelerating Growth: Unable to compare CU2's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CU2 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).


Return on Equity

High ROE: CU2 has a negative Return on Equity (-36.45%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 02:52
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cerus Corporation is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daniel OwczarskiAvondale Partners
Catherine Ramsey SchulteBaird
Mark MassaroBTIG